Skip to main content

Table 1 Inclusion/Exclusion Criteria

From: A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset™ or placebo

Inclusion Criteria
Diagnosis Type 2 Diabetes ≥ 6 months prior to enrollment
Age 30–80 years
Hba1c at screening ≤ 10
Male or Female Female of child bearing age must use definitive contraceptive therapy
Exclusion  
Taken Prescription sympathomimetic Taken seven days prior to screening
Drugs not permitted during study Ergot alkaloid derivatives, or anti-migrane medications
History of alcoholism or drug abuse Within 3 years of study entry
Donation of blood 30 days prior to study entry
Has received any experimental drug or used an experimental device Within 30 days of study entry
Pregnant or lactating women  
Known hypersensitivity to any of the formulation components  
Subjects with clinically significant major organ system disease:
• seizure disorder,
• significant gastroparesis or orthostatic hypotension (autonomic neuropathy),
• cerebrovascular accident in the previous 6 months,
• uncontrolled hypertension (systolic BP >160 or diastolic BP > 100 at screening)
• coronary artery bypass graft or coronary angioplasty in the previous 3 months, myocardial infarction in the previous 6 months, or unstable angina pectoris (chest pain at rest, worsening chest pain, or admission to the ER or hospital for chest pain) within the previous 3 months,
• congestive heart failure defined by NYHA as Class III or IV
• clinical nephrotic syndrome, or renal impairment with a serum creatinine > 1.4 mg/dl if female receiving treatment with metformin, > 1.5 mg/dl if male receiving treatment with metformin, and > 1.6 mg/dl in not on metformin,
• impaired liver function, including having AST or ALT greater than three times the upper limit of normal,
• active infection (e.g., HIV, hepatitis), or a history of severe infection during the 30 days prior to screening,
• major surgical operation during the 30 days prior to screening,
• cancer, other than non-melanoma skin or non metastatic prostate cancer within the past 5 years
• Any concurrent illness, other than diabetes mellitus, not controlled by a stable therapeutic regimen.
• Working rotating, varying or night shifts
• Patients taking unapproved herbal supplements that may be associated with a risk of cardiovascular events (such as ephedra, yohimbe etc)
• Patients who have started therapy with an erectile dysfunction drug within 2 weeks prior to screening; patients may not begin treatment with an erectile dysfunction drug during the study period; patients previously taking erectile dysfunction drugs should do so only under medical supervision.
• Subjects with circumstances or abnormalities (e.g., blindness or a history of non-compliance) that would interfere with the interpretation of safety or efficacy data or completion of the study.